CRO data quality decides how fast MIDD models reach regulators. See what a pharmacometric CRO survey reveals about sponsor data, costs, and AI-led fixes.
CRO data quality now shapes how fast pharmacometric models reach regulators. Most sponsor datasets arrive unfit for analysis and this affects cost, timelines, and the AI tools built to fix the problem.
Image
Why CRO Data Quality Sits at the Centre of MIDD
Model-informed drug development (MIDD) turns trial data into dosing decisions, trial designs, and regulatory arguments.
Every model rests on a dataset. If the dataset is flawed, the model is flawed, and the programme pays for it.
Data management activities, such as curation, quality assessment, and integration, all affect MIDD deliverables.
Regulators want these models too.
The U.S. Food and Drug Administration (FDA) has a MIDD Paired Meeting Program that runs across fiscal years 2023 to 2027.
The agency says MIDD approaches can improve trial efficiency, raise the probability of regulatory success, and support dose optimisation without dedicated trials.
As a result, the demand for models keeps rising and the quality of the data feeding them has not kept pace.
That affects every sponsor.
A delayed dataset delays the exposure-response analysis, the simulation, and the regulatory package built on top of them.
Additionally, small data problems at the start become large timeline problems at the end and pharmacometric teams feel this pressure first, because they receive the data last.
What pharmacometric CROs do
Pharmacometric CROs sit between the sponsor’s raw trial data and the final model.
They write data specifications, build analysis-ready datasets, check quality, and query the sponsor when something looks wrong. Only then does modelling begin.
However, a model can only be as good as the dataset.
“This is one of the riskiest industries there is because you're dealing with human lives, you're dealing with experimental protocols, and you're dealing with regulatory bodies where you might not get another shot at that clinical trial."
Image
What CROs Think About Sponsor Data
A 2026 research team sent an 11-question survey to 44 colleagues at 32 companies offering pharmacometrics services, including data management. Nine questions were multiple choice, and two were open-ended. Only seventeen people responded.
Most respondents develop data specifications and create analysis-ready datasets.
Notably, that sample is small, but it reflects a specialist corner of the CRO market, not the whole industry. Even so, the pattern unearthed is clear.
Most respondents said sponsor data was rarely usable on arrival.
Some 65% said the data they received was rarely immediately usable, which the survey defined as under 10% of the time. The causes included improper formatting, missing data, and inconsistencies.
The finding is really stark. An analysis-ready dataset follows a clear specification, uses consistent variables, and documents how it treats missing values.
For CROs that rarely receive data in that state, data cleaning becomes the default workflow rather than the exception.
The cost of data cleaning
Pharmacometric CROs face significant time and financial costs to curate and standardise poor-quality data from sponsors. Cleaning time also delays the modelling work that follows.
Moreover, CROs often work to tight timelines. Tight timelines limit thorough data verification and that raises the risk that errors reach the model itself.
Why the finding matters for sponsors
Data quality is also a sponsor problem. At the end of the day, it’s the sponsors who supply the data.
Every hour a CRO spends repairing files is an hour not spent on modelling and interpretation.
Sponsors pay for that time, directly or through slower decisions.
Better data at the start saves effort at every later stage. Pharmacometric teams who follow operational trends in drug development will recognise the theme, because the same pattern appears across Manufacturing, Supply, and Clinical Development.
Image
Where AI Helps and What Sponsors Should Do Next
Artificial Intelligence is not a panacea for poor data quality.
Automated data quality assessments can make checks more efficient but automation alone cannot resolve every issue.
Good communication, collaboration, and systematic approaches that combine automation and AI are all needed for good data quality.
A 2025 comparative review evaluated the impact of AI-based MIDD. Read together with the survey study, the two papers suggest that AI models are only as useful as the data they receive.
Documentation matters here too.
ICH M15 guidance, which the FDA announced in June 2026, includes recommendations on MIDD planning, model evaluation, and evidence documentation.
Traceable, well-structured data supports each of those steps, so sponsors that fix data quality now will find regulatory conversations easier later. For more on this theme, explore Pharmatica’s Technical Operations Insights.
Importantly, there must be understanding that AI readiness starts with data readiness.
Models that read inconsistent inputs produce inconsistent outputs.
Therefore, before piloting any AI tool, CRO and sponsor Data Leads should measure three baselines: How often data arrives analysis-ready, how many query cycles each dataset needs, and how long cleaning takes.
Those numbers show where automation will pay back first.
Where automation fits well
Rule-based checks handle repetitive work quickly. Examples include unit checks, duplicate detection, missing-value screening, and reconciliation against a data specification.
These tasks free programmers for harder problems.
Automation also creates a consistent audit trail, which helps when regulators ask how a dataset was built.
Where human judgement stays essential
An AI tool can flag a missing value but it cannot always explain why the value is missing.
For that it takes someone who understands the protocol, the assay, and the site.
Conflicts between sources also need expert review.
Teams that buy AI-enabled data services should ask vendors where the human checkpoints sit, and who signs off on each one.
Image
Actions for sponsors and CROs
Focusing on data quality lets CROs and sponsors cut data programming costs and improve financial outcomes.
The FDA created its MIDD pilot to encourage wider use of these principles.
Sponsors that want to use the programme need dependable datasets. Five steps can help:
Agree data standards early. Share specifications before data collection, not after database lock.
Build quality checks into data collection, so cleaning shrinks.
Give CROs time to verify data before modelling starts.
Set up a fast query loop between sponsor data managers and CRO programmers.
Track data cleaning hours as a programme metric.
None of these steps need new technology.
But they do need discipline, clear ownership, and early conversation between the teams that produce data and the teams that use it.
AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.
Image
Ensure Better Sponsor and CRO Data Quality
Sponsor data often arrives unfit for pharmacometric analysis, cleaning is costly, and tight timelines limit checks. AI and automation help, yet they need human expertise and stronger sponsor and CRO collaboration.
Teams that invest in CRO data quality early will move MIDD deliverables faster and spend less time and money on rework. That is a measurable operational gain.
It also builds trust between sponsors and CRO partners, which matters as MIDD moves from an option to an expectation. Data quality may look like a back-office topic. In practice, it decides how quickly a good model becomes a good decision.
At Pharmatica, we focus on the systems, partnerships, and technologies shaping pharmaceutical operations. Our Insights help decision-makers see where better data translates into faster, more confident development.
Pharmatica: Insight. Connection. Impact.
Frequently Asked Questions
What is CRO data quality in pharmacometrics?
CRO data quality in pharmacometrics describes how complete, consistent, and well formatted trial data are when a CRO receives them. Pharmacometric teams need analysis-ready datasets to build MIDD models. Poor data quality slows that work, raises costs, and increases the risk of errors reaching the final model.
Why do sponsor datasets need so much cleaning?
Any improper formatting, missing data, and inconsistencies can require extensive data cleaning. Some 65% of CRO respondents have said that sponsor data was rarely immediately usable. CROs then spend time curating and standardising files before analysis can start. Poor formatting and inconsistent structure make that work slow and manual.
How does poor data quality affect MIDD timelines and costs?
Data cleaning adds hours before modelling begins. Tight timelines limit verification, which raises the risk of downstream errors. This can all result in significant time and financial costs for CROs, and those costs ultimately affect sponsors.
Can AI fix clinical trial data quality problems?
AI can help, but it cannot fix everything. Automated assessments improve efficiency, yet automation alone cannot resolve all quality issues. Better communication, collaboration, and systematic approaches must sit alongside the technology.
How can sponsors improve the data they send to CROs?
Sponsors should agree data standards early, share specifications before collection begins, and build checks into the collection process. Allow time for verification. Keep a direct query channel open with the CRO team. Tracking cleaning hours also shows which data sources cause the most rework.
Nicole (BSc Molecular Medicine, Honours Medical Biochemistry) has many years of pharmaceutical experience, having worked for top CROs and biopharma companies for more than a decade.
Did you enjoy the content?
1
Why not support
Nicole Dale
by giving this content a like
Collaboration in drug discovery can shape pharma R&D success. Explore the evidence on pharma partnerships, knowledge sharing, governance, and innovation.
Find out how q-CAR drug discovery moves beyond static protein structures by linking protein dynamics, ligand activity, and AI to precision drug design.
FDA 2026 Draft Guidance on Alternatives to Animal Testing
The FDA's March 2026 draft guidance on alternatives to animal testing marks a pivotal shift in preclinical drug development. Here's what pharma R&D teams need to know.
Optimising Preclinical Pharmacology for Oncology NMEs
Over 90% of oncology NMEs that succeed in animal studies fail in clinical trials. This analysis examines how to optimise preclinical pharmacology models to improve translational success.
Success for Non-Animal Testing of Preclinical Toxicity?
Can non-animal testing methods be used in preclinical drug discovery? Here is what the evidence is for their accuracy and limits assessing preclinical toxicity.
Comments (0)